This Week's IPOs Part II: Sirtris Pharmaceuticals, STARLIMS Technologies

Two more IPOs are on deck for this week: Sirtris Pharmaceuticals (SIRT), a biotech that focuses on small molecule drugs; and STARLIMS Technologies (LIMS) an provider of laboratory information management systems based in Israel.

All quotations are from the companies' most recent S-1 filings with links provided.

SIRTRIS PHARMACEUTICALS, INC. (SIRT)
Business Overview (from prospectus)

We are a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activating an enzyme called SIRT1, a member of a recently discovered class of enzymes called sirtuins. Over the past 70 years, scientists have shown that calorie restriction, or the reduction of normal calorie intake by at least 30-40%, extends lifespan in multiple species, including mice and rats. In addition, calorie restricted animals showed improvement in a number of factors associated with Type 2 Diabetes, including glucose levels, insulin levels and weight gain. Recently published animal studies, including articles in Cell and Nature in 2006, suggest that certain beneficial effects of calorie restriction are triggered by activation of SIRT1.

Offering: 5.0 million shares at $9.00 - $11.00 per share. Net proceeds of approximately $44.8 million will be used to continue the clinical development into Phase 2 of SRT501 for diabetes, MELAS and, potentially, other indications (approximately $13.5 million); to advance and expand preclinical studies and potentially initiate clinical development of additional product candidates targeting SIRT1; to expand research and preclinical development programs targeting other sirtuins and related pathways ; to repay existing debt facilities pursuant to their existing terms, including interest and for general corporate purposes.

Lead Underwriters: J.P. Morgan, CIBC World Markets

Financial Highlights:

We did not record any revenue for the three months ended March 31, 2007 (2007 Quarter) or the three months ended March 31, 2006 (2006 Quarter)....Research and development expense for the 2007 Quarter was $5.1 million compared to $3.2 million for the 2006 Quarter.

STARLIMS TECHNOLOGIES (LIMS)
Business Overview (from prospectus)

We are a leading provider of laboratory information management systems, or LIMS, and have over 20 years experience in the LIMS market. We develop, market and sell configurable off-the-shelf LIMS software solutions trade-named STARLIMS®. STARLIMS manages the collection, processing, storage, retrieval and analysis of information generated in laboratories. Our software improves the reliability of sampling processes, supports compliance with domestic and international regulations and industry standards, and provides comprehensive reporting, monitoring and analysis capabilities. We are one of the first LIMS vendors to offer a true web-based, configurable off-the-shelf, LIMS solution, which enables our customers to manage their globally distributed laboratories more efficiently and effectively.

Offering: 2.1 million shares at $13.50 - $15.50 per share. Net proceeds of approximately $25.9 million will be used for general corporate purposes, including working capital and capital expenditures.

Lead Underwriters: Oppenheimer & Co., JMP Securities

Financial Highlights:

Revenues increased from $16.2 million for the year ended December 31, 2005 to $19.8 million for the year ended December 31, 2006, an increase of 22%... Cost of services increased from $3.4 million for the year ended December 31, 2005 to $5.6 million for the year ended December 31, 2006, an increase of 63%... Gross profit as a percentage of revenues decreased from 79% for the year ended December 31, 2005 to 72% for the year ended December 31, 2006...Financial income, net increased from $271,000 for the year ended December 31, 2005 to $610,000 for the year ended December 31, 2006, an increase of 125%.